Buch, Englisch, 392 Seiten, Format (B × H): 151 mm x 230 mm, Gewicht: 569 g
Buch, Englisch, 392 Seiten, Format (B × H): 151 mm x 230 mm, Gewicht: 569 g
Reihe: European Observatory on Health
ISBN: 978-0-335-21465-5
Verlag: McGraw-Hill Publishing Company
"This thoughtful and comprehensive book represents the best work I have seen on the current situation concerning medication policies in the EU. It is not just that this is a very up-to-date compendium of facts and data across a wide variety of domains that impact on pharmaceutical regulation. The book is also strong on analysis of those facts as well."
Jerry Avorn, Harvard Medical School. "This book offers a comprehensive examination of approaches to manage pharmaceutical expenditures in Europe. It is a must-read for those who seek to understand and navigate the changing regulatory environment for medicines in the European Union."
Bernie O'Brien, McMaster University, Canada. The rising cost of pharmaceutical expenditures in many European countries is of concern to governments required to make effective use of health care budgets. Taking a broad perspective that encompasses institutional, political and supranational aspects of pharmaceutical regulation, this book examines approaches used to manage pharmaceutical expenditure across Europe and what impact these strategies have had on efficiency, quality, equity and cost of pharmaceutical care.Regulating Pharmaceuticals in Europe is an important book for students of health policy, regulation and management, and for health managers and policy makers.The editors:
Elias Mossialos is Brian Abel-Smith Professor of Health Policy at the London School of Economics and Political Science and a Research Director of the European Observatory on Health Systems and Policies.Monique Mrazek is a Health Economist (Europe and Central Asia region) for the World Bank and formerly a Research Officer in Health Economics for the European Observatory on Health Systems and Policies.Tom Walley is Professor of Clinical Pharmacology at the University of Liverpool and Director of the UK National Health Technology Assessment Programme.Contributors: Julia Abelson, Christa Altenstetter, Vittorio Bertele’, Christine Bond, Marcel L. Bouvy, Colin Bradley, Steve Chapman, Anna Dixon, Michael Drummond, Pierre Durieux, Edzard Ernst, Armin Fidler, Eric Fortess, Richard Frank, Silvio Garattini, Leigh Hancher, Ebba Holme Hansen, Steve Hudson, Kees de Jonchere, Panos Kanavos, Sjoerd Kooiker, Jean-Marc Leder, Graham Lewis, Donald W. Light, Alistair McGuire, Elias Mossialos, Monique Mrazek, Maria Pia Orru', Govin Permanand, Guenka Petrova, Munir Pirmohamed, Dennis Ross-Degnan, Frans Rutten, Steven Soummerai, David Taylor, Sarah Thomson, Tom Walley.
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
List of boxes, figures and tables
List of contributors
Series editors’ introduction
Foreword
Preface
Acknowledgments
Regulating pharmaceuticals in europe: an overview
The politics of pharmaceuticals in the European Union
The European Community dimension: co-ordinating divergence
The role of the EMEA in regulating pharmaceutical products
Measuring, monitoring and evaluating policy outcomes in the pharmaceutical sector
Regulating pharmaceutical prices in the European Union
Reimbursement of pharmaceuticals in the European Union
Good prescribing practice
Patients and their medicines
Financial incentives and prescribing
Regulating pharmaceutical distribution and retail pharmacy in Europe
Hospital pharmacies
Influencing demand for drugs through cost sharing
The off-patent pharmaceutical market
The over-the-counter pharmaceutical market
The implications of pharmacogenetics and pharmacogenomics for drug development and health care
Should we pay for life-style drugs?
Alternative medicines in Europe
The pharmaceutical sector and regulation in the countries of Central and Eastern Europe
Access to pharmaceuticals and regulation in the Commonwealth of Independent States
A framework for containing costs fairly
Index.
